Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients

BACKGROUND: The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan’s demographic structure is becoming pronounced. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Hideki, Suzuki, Hidekazu, Omata, Fumio, Masaoka, Tatsuhiro, Asaoka, Daisuke, Kawakami, Kohei, Mizuno, Shigeaki, Kurihara, Naoto, Nagahara, Akihito, Sakaki, Nobuhiro, Ito, Masayoshi, Kawamura, Yo, Suzuki, Masayuki, Shimada, Yuji, Sasaki, Hitoshi, Matsuhisa, Takeshi, Torii, Akira, Nishizawa, Toshihiro, Mine, Tetsuya, Ohkusa, Toshifumi, Kawai, Takashi, Tokunaga, Kengo, Takahashi, Shin’ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611030/
https://www.ncbi.nlm.nih.gov/pubmed/31320930
http://dx.doi.org/10.1177/1756284819858511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611030/
https://www.ncbi.nlm.nih.gov/pubmed/31320930
http://dx.doi.org/10.1177/1756284819858511

Ejemplares similares